- Home
- DMF vs CRVO Comparison
DMF vs CRVO Comparison
Compare DMF & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- CRVO
- Stock Information
- Founded
- DMF 1988
- CRVO 2001
- Country
- DMF United States
- CRVO United States
- Employees
- DMF N/A
- CRVO N/A
- Industry
- DMF Finance/Investors Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- CRVO Health Care
- Exchange
- DMF Nasdaq
- CRVO Nasdaq
- Market Cap
- DMF 149.3M
- CRVO 160.4M
- IPO Year
- DMF N/A
- CRVO N/A
- Fundamental
- Price
- DMF $7.23
- CRVO $9.58
- Analyst Decision
- DMF
- CRVO Strong Buy
- Analyst Count
- DMF 0
- CRVO 6
- Target Price
- DMF N/A
- CRVO $53.67
- AVG Volume (30 Days)
- DMF 60.7K
- CRVO 78.8K
- Earning Date
- DMF 01-01-0001
- CRVO 11-12-2024
- Dividend Yield
- DMF 2.66%
- CRVO N/A
- EPS Growth
- DMF N/A
- CRVO N/A
- EPS
- DMF 0.15
- CRVO N/A
- Revenue
- DMF N/A
- CRVO $10,066,550.00
- Revenue This Year
- DMF N/A
- CRVO $54.67
- Revenue Next Year
- DMF N/A
- CRVO N/A
- P/E Ratio
- DMF $45.13
- CRVO N/A
- Revenue Growth
- DMF N/A
- CRVO 116.29
- 52 Week Low
- DMF $5.37
- CRVO $5.85
- 52 Week High
- DMF $6.79
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- DMF 49.40
- CRVO 27.48
- Support Level
- DMF $7.18
- CRVO $9.31
- Resistance Level
- DMF $7.27
- CRVO $11.44
- Average True Range (ATR)
- DMF 0.08
- CRVO 0.90
- MACD
- DMF 0.01
- CRVO -0.23
- Stochastic Oscillator
- DMF 66.07
- CRVO 6.34
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.